Orion OYJ Unsponsored ADR (OTCMKTS:ORINY - Get Free Report) shares were down 1.2% on Wednesday . The stock traded as low as $37.09 and last traded at $37.09. Approximately 124 shares were traded during trading, a decline of 14% from the average daily volume of 144 shares. The stock had previously closed at $37.53.
Orion OYJ Stock Performance
The company has a debt-to-equity ratio of 0.27, a current ratio of 3.79 and a quick ratio of 2.27. The company's 50-day moving average price is $32.81 and its two-hundred day moving average price is $28.59. The company has a market capitalization of $10.47 billion, a price-to-earnings ratio of 28.31 and a beta of 0.07.
Orion OYJ (OTCMKTS:ORINY - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The company reported $0.23 earnings per share for the quarter. Orion OYJ had a net margin of 21.74% and a return on equity of 36.23%. The company had revenue of $373.03 million during the quarter. On average, equities research analysts anticipate that Orion OYJ Unsponsored ADR will post 1.18 EPS for the current fiscal year.
About Orion OYJ
(
Get Free Report)
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Orion OYJ, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Orion OYJ wasn't on the list.
While Orion OYJ currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
